Evidence map›Paper›PMID 39607549›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Quercetin is a potential therapy for post-infarction NETosis formation.

Y Goshovska, D Pashevin, S Goncharov, T Lapikova-Bryhinska, O Lisovyi, V Nagibin, G Portnichenko, L Tumanovska, V Dosenko

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Y GoshovskaDepartment of Blood Circulation, Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kyiv, 01024, Ukraine. goshovska@biph.kiev.ua.ORCID 0000-0003-3308-9091
D PashevinDepartment of General and Molecular Pathophysiology, Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine.
S GoncharovDepartment of General and Molecular Pathophysiology, Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine.
T Lapikova-BryhinskaDepartment of General and Molecular Pathophysiology, Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine.
O LisovyiDepartment of Blood Circulation, Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kyiv, 01024, Ukraine.
V NagibinDepartment of General and Molecular Pathophysiology, Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine.
G PortnichenkoDepartment of General and Molecular Pathophysiology, Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine.
L TumanovskaDepartment of General and Molecular Pathophysiology, Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine.
V DosenkoDepartment of General and Molecular Pathophysiology, Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The surgical intervention during myocardial infarction (MI) is associated with the risk of reperfusion injury, infiltration of tissues with polymorphonuclear neutrophils, and neutrophil extracellular trap (NET) formation. We hypothesized that inhibition of NETs with the use of quercetin might be a promising cardioprotective strategy. Wistar rats underwent LAD occlusion (MI) for 40 min followed by 90 min of reperfusion. The MI + Q group received a water-soluble form of quercetin (50 mg/kg, "Corvitin," BCPP, Ukraine) into the tail vein 10 min before reperfusion. The post-MI administration of quercetin significantly alleviated cardiac dysfunction. End-systolic pressure, stroke volume, cardiac output, and stroke work were significantly improved in the MI + Q vs. MI group. NET formation (examined by fluorescence microscopy and Hoechst staining) as well as free DNA in blood plasma was reduced in the MI + Q group that might be one of the mechanisms of the cardioprotective effect of quercetin. Postconditioning with quercetin might be used as a therapeutic tool for the alleviation of reperfusion injury and NETosis inhibition in vivo.

Indexed as

AntioxidantsCardiotonic AgentsExtracellular TrapsMyocardial InfarctionMyocardial Reperfusion InjuryQuercetinAnimalsDNAMaleNeutrophilsRatsRats, WistarAntioxidantsCardiotonic AgentsDNAQuercetinHeartIschemiaMyocardial infarctionNETosisQuercetinReperfusion

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.